SPECT market seen reaching $3.92 billion by 2030

The single-photon emission computed tomography market is projected to grow from $2.5 billion in 2025 to $3.92 billion by 2030, as demand rises for advanced molecular imaging, precision diagnostics and early disease detection. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - SPECT is becoming more important as hospitals and diagnostic centers look for better tools to detect disease earlier and monitor treatment. - The market’s projected growth points to stronger demand for nuclear medicine and advanced imaging across oncology, cardiology and neurology. - Rising cancer rates are increasing the need for diagnostic technologies that can support staging, tracking and treatment decisions.

What happened: - The global single-photon emission computed tomography market was valued at $2.5 billion in 2025. - The market is projected to reach $2.73 billion in 2026. - The market is forecast to reach $3.92 billion by 2030. - The projected compound annual growth rate is 9.5% from 2026 through 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - Download a free sample of the report. - View the full market report.

The details: - SPECT uses radioactive tracers and gamma rays to produce three-dimensional images of organs and tissues. - A gamma camera detects rays emitted by the tracer and supports non-invasive internal imaging. - The technology is used to diagnose and monitor a range of medical conditions. - Historical growth was driven by broader use of nuclear medicine, more diagnostic imaging procedures, higher rates of cardiovascular and neurological disease, hospital investment in imaging infrastructure and wider use of radioisotope-based diagnostics. - Future growth is expected to come from demand for advanced molecular imaging, precision diagnostics, outpatient diagnostic center expansion, AI integration in medical imaging and stronger emphasis on early disease detection. - Cancer Australia reported about 8,257 new melanoma cases in 2023, and melanoma accounted for 2.6% of cancer-related deaths in Australia. - SPECT is used with CT and MRI to help diagnose, stage and track cancer progress. - The report says 2026 editions include market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics and updated technology and trend analysis.

Between the lines: - The market outlook suggests SPECT is moving from a specialized imaging tool toward a broader role in routine diagnostic workflows. - AI adoption in medical imaging could sharpen SPECT’s value proposition by improving image interpretation and clinical efficiency. - North America’s lead reflects established healthcare infrastructure, while Asia-Pacific’s growth points to rising access and spending in emerging markets.

What's next: - The market’s expansion will likely depend on continued hospital investment, wider outpatient adoption and further integration of imaging software tools. - Rising disease burden, especially cancer, is likely to keep demand elevated for precise diagnostic imaging. - Regional growth in Asia-Pacific may reshape where new SPECT capacity is added over the next several years.